Meeting
2018 ASCO Annual Meeting
Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).
Authors
Laura Locati
Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Laura Locati , Carmela Aves Caballero , Catherine Fortpied , Federica Perrone , Pasquale Quattrone , Kevin Harrington , Vincent Gregoire , Lisa F. Licitra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT01969578
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS6099)
DOI
10.1200/JCO.2018.36.15_suppl.TPS6099
Abstract #
TPS6099
Poster Bd #
82b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
First Author: Susumu Okano
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel
Poster
2023 ASCO Annual Meeting
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.
First Author: Carla M.L.- Van Herpen
Poster
2023 ASCO Annual Meeting
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
First Author: Maliheh Mohamadpour